Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Business Insider India5y
Pharma CEOs got into a heated debate over why people hate the industry
The panel featured Gilead CEO John Milligan, Pfizer CEO Ian Read, incoming Eli Lilly CEO David Ricks, Astellas Americas President Jim Robinson, and Regeneron CEO Leonard Schleifer. After some ...
Hosted on MSN7mon
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
“Regeneron had a strong quarter, with total revenue up 12% driven by notable growth for EYLEA HD, Dupixent, and Libtayo,” said Leonard S. Schleifer, Board co-Chair, President and Chief ...